GOLDEN, CO / ACCESSWIRE / March 26, 2020 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations.
Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 1st comparative quarter in Total Revenues. Vitro Biopharma recorded 1st quarter revenues of $225,921 vs $192,895 an increase of 17% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 74% of the revenues up from 71% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $167,750 for the 1st quarter ended January 31, 2020 vs $137,123 for the first quarter ended January 31, 2019.
The company's gross profit margins improved to 75% up from 73% in the comparative prior year's quarter. Gross margin improvement is in line with the strategic direction of the company to expand the market of its flagship product AlloRx Stem Cells. The company's clean-room lab expansion last year and expanded Stem Cell manufacturing using its patent-pending cell line, has increased efficiencies and lowered production costs.
Overall operating expenses increased in the quarter to $193,385 from $147,398 in the prior year's comparative quarter. The increase in expenses reflects additional investment as the Company expands its capability to service its strategic direction of offshore Stem Cell treatments while also expanding into US markets. The company expended additional resources on external consultants supporting our regulatory status in maintaining ISO9001 & ISO13485 certifications, expanding our efforts to approach US markets through FDA filings and advancement of existing patent filings.
The company's first quarter is its most seasonal quarter as the period between Thanksgiving and the New Year is slow for all the company's revenue lines of Nutra Vivo/STEMulize, AlloRx Stem Cells, private labeled InfiniVive-MD Stem Cell Serum and our core research products.
During the quarter the company achieved and pursed the following company objectives
During the quarter the company commenced a Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $450,000 of the Series A Convertible Preferred Stock during the quarter. The company has additional interest in the offering and subsequent to the quarter has sold an additional $50,000 unit for a total to date of $500,000. The company has additional interested parties for approximately $200,000. The offering is for a total of $1,000,000.
Our partnership with DVC. Stem in the Cayman Islands continued to advance through treatment of new & previous patients. This IRB-approved protocol targets patients with inflammatory conditions including multiple sclerosis, systemic inflammation and new indications including Chrohn's disease, Alzheimer's disease and COPD. To date we have treated 60 patients including repeat treatments. There have been no serious adverse events and we continue to gain evidence of efficacy. One of the initial MS patients has now received a second transplant of our AlloRx Stem Cells and he has reported significant therapeutic benefits of both the initial and subsequent therapy. He had received an earlier transplant of adipose-derived MSCs that was effective, but the improvement lasted 3 months while AlloRx Stem Cell therapy lasted 18 months. We had predicted such a clinical outcome based on significantly higher potency of umbilical cord MSCS compared to those derived from adipose tissue or bone marrow. The Chrohn's disease patient showed significant improvement as did both the AD & COPD patients.
The strategic development of our stem cell therapies involves pursuit of both offshore and domestic markets. The partnership with DVC Stem, our IRB-approved trial in the Bahamas together with other strategic opportunities represent offshore operations & prospects. During Q1 2020, we initiated expansion into US therapeutic markets through development of an Investigational New Drug (IND) application for submission to FDA. Once approved, an IND allows the conduct of clinical trials for specific medical conditions in the US.
Story continues
Given the current COVID-19 pandemic, our initial IND application is for use of AlloRx Stem Cells in treatment of Coronavirus infections. This is supported by clinical studies showing that 17 critically ill patients responded favorably to IV infusion of umbilical cord-derived MSCs. All patients were receiving assisted ventilation but 3 days following stem cell therapy, were removed from ventilators and subsequently discharged from the hospital. We are pursuing discussions with FDA to establish the appropriate regulatory pathway and expedited review options given the current emergency circumstances. (See Subsequent Events, below, for additional discussion of our COVID-19 response.) Once our initial IND is in place, we have plans for additional INDs for stem cell therapy of musculoskeletal conditions and Alzheimer's disease.
We have received an initial order of AlloRx Stem Cells for testing purposes by PR Medica located in Cabo San Lucas. Given successful test results, we anticipate subsequent new revenue generation from this customer.
Vitro Biopharma's cosmetic topical stem cell serum is being distributed by InfiniVive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in 10 cosmetic clinics.
Our partner, Dr Jack Zamora, MD was a keynote speaker at a master session at the American Academy of Cosmetic Surgery annual meeting in late February. The topic of his presentation was "Topical Stem Cells, Exosomes and Conditioned Media Serums in Aesthetics." This was the official launch of the InfiniVive-MD platform including: Dailey Serum, Stem Cell Serum 2.0 & Exosomes within the product line. Vitro Biopharma will manufacture & private label these new products for distribution in the US. We anticipate InfiniVive MD growth, development and revenues to mirror the development of Apyx subdermal plasma skin tightening as a cosmetic treatment and technique that has gone global.
http://www.jackzamoramd.com http://www.infinivivemd.com
Our core research product sales continued to expand in Q1 2020. Our facility expansion continued with addition of manufacturing capacity and development of plans to add operational facility to increase outputs further by 100% or more. We were also in discussions with the USPTO regarding our pending patents for our novel stem cell therapy and stem cell activation technology. We continue to work closely with our examiner and have established communication channels to facilitate awards of these patents.
The COVD-19 pandemic is a significant obstacle for all business. However, Vitro Biopharma is uniquely positioned since we have a potential effective therapy. This is based on 3 independent reports showing efficacy of stem cell therapy in 17 COVID-19 patients. All were treated with IV umbilical cord MSCs comparable to AlloRx Stem Cells and all 17 required respiratory assistance but within 3-4 days of treatment, were able to breath without ventilators and were discharged within 14 days. https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese-patient-saved-stem-cell On the contrary, untreated patients on ventilators have death rates of 50% or more. We have received a formal request to supply AlloRx Stem Cells for compassionate use from a major university medical center and several other potential clinical partners have also expressed interest in using our cells to treat COVID-19 patients. We are presently working with the FDA to gain authority to begin clinical testing in the US. We are currently assessing the overall financial impact of the COVID-19 pandemic on our business, but this depends on overall control of the pandemic. There have been no staff layoffs and our workers are considered essential since we conduct essential research to the COVID-19 response.
Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are very pleased with the increased revenue growth during our first quarter 2020 compared to the prior year However all our resources are currently focused on the emergency response to the COVID-19 pandemic and increasing our inventory of AlloRx to satisfy anticipated emergency demand to treat critically ill COVID-19 patients." The Company is working to get expedited clinical trial approvals to sell our AlloRx Stem Cells to hospitals coping with the pandemic. Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus". https://bioinformant.com/product/coronavirus-covid-19-report/ We anticipate clinical progress in the effectiveness of our stem cell therapies while expecting to see a reduction in our offshore and cosmetic revenues for the next quarter or two. The company is in a good cash position to weather this storm and simultaneously advance its AlloRx stem cell therapies into clinical trials.
In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10- years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We are leveraging our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.
Sincerely yours,
James R. Musick, PhD.President, CEO & Chairman of the Boardwww.vitrobiopharma.com
Forward-Looking Statements
Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Dr. James MusickChief Executive OfficerVitro BioPharma(303) 999-2130 Ext. 3E-mail: jim@vitrobiopharma.comwww.vitrobiopharma.com
The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant
The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant
The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.
The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.
SOURCE: Vitro Diagnostics, Inc.
View source version on accesswire.com: https://www.accesswire.com/582759/Vitro-Biopharma-First-Quarter-ended-January-31-2020-Financial-Results-of-Operations
Read more:
Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Yahoo Finance
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 21st, 2024
- Harvard Stem Cell Institute (HSCI) - December 29th, 2023
- Stem cell - Wikipedia - December 29th, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Focus On Stem Cell Research | National Institute of Neurological ... - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of... - October 21st, 2022
- NIH Guidelines for Human Stem Cell Research - October 13th, 2022
- Ethics of Stem Cell Research - Blue Marble Space Institute of Science - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Stem Cell Therapy Market (2022-2029) Size Will Escalate Rapidly in the Near Future: Osiris Therapeutics, Molmed - Digital Journal - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research - October 13th, 2022
- Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector - ResearchAndMarkets.com -... - October 13th, 2022
- Nancy and Geoffrey Stack Family Foundation give $2 million to UCI Health - UCI News - October 4th, 2022
- Cell Isolation Market is expected to generate a revenue of USD 20.50 Billion by 2028, Globally, at 15.70% CAGR: Verified Market Research -... - September 25th, 2022
- Creating stem cells from minipigs offers promise for improved treatments - University of Wisconsin-Madison - September 16th, 2022
- Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board - Yahoo Finance - September 16th, 2022
- Genomics study identifies unique set of proteins that restores hearing in zebrafish - National Institutes of Health (.gov) - September 16th, 2022
- Discovered Key Mechanisms to Improve Intestinal Regeneration and Alleviate the Side Effects of Radiotherapy - Imaging Technology News - September 16th, 2022
- Global Cell Expansion Market Size to Grow at a CAGR of 15% during the Forecast Period 2022-2027 - Digital Journal - September 16th, 2022
- The American Cancer Society Awards $2.1 Million to Montefiore Einstein Cancer Center to Support Cancer Research and Tackle Inequities - Yahoo Finance - September 16th, 2022
- Hair Restoration Market | Stem Cell hair Restoration and Low-level Laser Therapy (LLLT) segment are Expected to Witness Significant CAGR - MDC... - August 30th, 2022
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - August 5th, 2022
- 'Off the shelf' CAR T cells for cancer treatment? - Boston Children's Answers - Boston Children's Discoveries - August 5th, 2022
- Inflammation accelerates aging of the hematopoietic system - EurekAlert - August 5th, 2022
- New patent-pending method mass-produces antitumor cells to treat blood diseases and cancer - Purdue University - August 5th, 2022
- Cell Therapy Technologies Market worth $8.0 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - August 5th, 2022
- Twenty-Five Years After My House Call To Dolly: What Have We Learned About Cloning And How Did We Learn It? - Forbes - August 5th, 2022
- Tendon Stem Cell Therapy Market is Booming Worldwide with Strong Growth Prospects | Cellualar Dynamics, Cellectis, International Stem cell... - July 27th, 2022
- [Pangyo Bio & Medical] Theragen Bio discovers MAST4 Protein that Regulates Bone Cartilage Development For 'The First Time in The World' - Digital... - July 27th, 2022
- Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. - PR Newswire - July 27th, 2022
- Cryopreservation Equipment Market Report 2022-2028: Importance of Cryopreservation for Success of Cell-Based Therapies Presents Opportunities -... - July 27th, 2022
- Whitmer axes stem cell research, pregnancy center funding over abortion access concerns - MLive.com - July 19th, 2022
- Stem Cell - National Human Genome Research Institute Home - July 11th, 2022
- Induced Pluripotent Stem Cells (iPS) | UCLA Broad Stem Cell Center - July 11th, 2022
- Global 3D Cell Culture Market To Be Driven By Growing Impact Of Economy On Regenerative Medicine, Emerging Applications Of Gene Therapy During The... - July 11th, 2022
- New Combination Therapy Effective in Pediatric Leukemia - Technology Networks - June 22nd, 2022
- MIT Pioneers Technology To Grow Customizable Wood Products in the Lab With Little Waste - SciTechDaily - June 22nd, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 13th, 2022
- Scientists hope this injectable stem cell gel can repair heart attack damage and avoid transplants - Euronews - June 13th, 2022
- Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery - Business Wire - June 13th, 2022
- Fasting has pros and cons for muscle repair in mice - Futurity: Research News - June 13th, 2022
- First Clinical Trial of Transplanted 3D Ear Using Human Cells Proves Successful via 3DBio Therapeutics - Tech Times - June 4th, 2022
- Insights on the Dimethyl Sulfoxide (DMSO) Global Market to 2027 - Expanding Research and Development in Stem Cell Transplantation to Benefit Demand... - May 15th, 2022
- Scientists Rejuvenate Skin Cells by 30 Years, with Pioneering Potential - BioSpace - May 15th, 2022
- Global Flow Cytometry Market is expected to grow at a lucrative rate of 8% to reach $11 billion by 2026 A Robust Tool that Defines New Era for... - May 15th, 2022
- Global Mesenchymal Stem Cells Market Research Report to 2027 - Featuring Astellas Pharma, Axol Biosciences and BrainStorm Cell Therapeutics Among... - May 2nd, 2022
- Researchers share insights about the mechanisms of human embryo and create method to develop transcriptionally similar cells in tissue culture -... - May 2nd, 2022
- Flow Cytometry Market is Estimated Drive the Industry Growth Across World in Coming Year 2030 Queen Anne and Mangolia News - Queen Anne and Mangolia... - May 2nd, 2022
- Mini-heart chamber beats on its own just like the real thing - Futurity: Research News - May 2nd, 2022
- The Case Against Embryonic Stem Cell Research: An ... - April 6th, 2022
- Burst of accumulated zinc shows how the mineral boosts immune function, suggesting ways to improve health - EurekAlert - April 6th, 2022
- Hoyer Statement on the Retirement of Congressman Fred Upton - Majority Leader - April 6th, 2022
- 11 Stem Cell Research Pros and Cons Vittana.org - March 25th, 2022
- Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 - Times Higher Education - March 25th, 2022
- Google still has a problem with stem cell and unproven therapies - STAT - STAT - March 25th, 2022
- Medeze Named Frost & Sullivan's 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry - PR Newswire - March 25th, 2022
- Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry... - March 25th, 2022
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Future Business Opportunities 2022-2028 | Caladrius Biosciences, Vericel Corporation,... - March 25th, 2022
- Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data - Digital Journal - March 25th, 2022
- This Fancy AF Face Cream Was Invented by a Stem Cell Researcher - VICE - March 25th, 2022
- Freeze Thaw Chambers Market: The cryopreserved products segment is expected to drive the growth of the market - BioSpace - January 5th, 2022
- As Nave as They Get - Weizmann Wonder Wander - News, Features and Discoveries - Weizmann Institute of Science - January 5th, 2022
- Jake's mice: Searching for answers to the puzzle of autism - huntingdondailynews.com - January 5th, 2022
- Primary Cells, Stem Cells, Culture Media and Reagents Market to Witness Rapid Growth by 2029 | BrainStorm Cell Therapeutics Inc., Caladrius... - January 5th, 2022
- Gait Rehabilitation System Market: Rising incidence of various neurological disorders to drive the market - BioSpace - January 5th, 2022
- ARVO Foundation Announces 2022 Bert M. Glaser, MD Award for Innovative Retina Research Recipient - Newswise - January 5th, 2022
- Communication between cells plays a major role in deciding their fate - EurekAlert - December 24th, 2021
- The 10 Most Compelling Research Stories of 2021 - BioSpace - December 24th, 2021
- MRC Lead Apologizes Following Bullying Allegations - The Scientist - December 24th, 2021
- California Proposition 14, Stem Cell Research Institute ... - November 22nd, 2021
- Ethical Issues in Stem Cell Research - PubMed Central (PMC) - November 22nd, 2021
- Opinion | How Covid Raised the Stakes of the War Between Faith and Science - The New York Times - November 8th, 2021
- What is Stem Cell Research? | The Benefits of Stem Cell Research - October 5th, 2021
- An Overview of Stem Cell Research | The Center for Bioethics ... - October 5th, 2021
- Stem Cell Research: Uses, Types & Examples - October 5th, 2021
- Stem Cells | National Institutes of Health (NIH) - October 5th, 2021
- Stem cells: Therapy, controversy, and research - October 5th, 2021